The relationship between serum and sputum levels of azithromycin and clinical endpoints in patients with bronchiectasis using azithromycin maintenance treatment
Open Access
- 16 July 2019
- journal article
- Published by Heighten Science Publications Corporation in Archives of Pharmacy and Pharmaceutical Sciences
- Vol. 3 (1), 019-025
- https://doi.org/10.29328/journal.apps.1001014
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trialThorax, 2013
- Azithromycin maintenance therapy in patients with cystic fibrosis: A dose advice based on a review of pharmacokinetics, efficacy, and side effectsPediatric Pulmonology, 2012
- Azithromycin for Prevention of Exacerbations of COPDThe New England Journal of Medicine, 2011
- Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patientsJournal of Cystic Fibrosis, 2008
- Daily versus weekly azithromycin in cystic fibrosis patientsEuropean Respiratory Journal, 2007
- Comparative Pharmacokinetics of Azithromycin in Serum and White Blood Cells of Healthy Subjects Receiving a Single-Dose Extended-Release Regimen versus a 3-Day Immediate-Release RegimenAntimicrobial Agents and Chemotherapy, 2007
- Pharmacokinetics of Azithromycin in Plasma, Blood, Polymorphonuclear Neutrophils and Sputum During Long-Term Therapy in Patients With Cystic FibrosisTherapeutic Drug Monitoring, 2006
- Absolute Bioavailability and Intracellular Pharmacokinetics of Azithromycin in Patients with Cystic FibrosisAntimicrobial Agents and Chemotherapy, 2005
- Standardisation of spirometryEuropean Respiratory Journal, 2005
- PHARMACOKINETICS OF AZITHROMYCIN IN LUNG TISSUE, BRONCHIAL WASHING, AND PLASMA IN PATIENTS GIVEN MULTIPLE ORAL DOSES OF 500 AND 1000 MG DAILYPharmacological Research, 2002